Neurolief develops non-invasive neuromodulation therapies and is focused on delivering clinically validated treatments that expand access to care. Its lead product, Proliv™Rx, received FDA Premarket Approval in December 2025 as the first FDA-approved prescription, at-home brain neuromodulation system for adults with major depressive disorder who have not achieved adequate response to at least one antidepressant. Proliv™Rx is prescribed and supervised by physicians while being self-administered by patients at home, intended to overcome access barriers tied to clinic-dependent delivery models. Following FDA approval, Neurolief reported early commercial traction and is using recent investment to accelerate U.S. rollout and scale its at-home therapy model. The company framed its strategy around bridging care gaps and supporting health systems shifting toward value-based care.

Total raised

$6M

Funding rounds

2

Latest round

Equity

Latest activity

Mar 2026